薛增明,马长生,刘新民,康俊萍,聂绍平,董建增

• 1:首都医科大学附属北京安贞医院心内科
• 2:河北省廊坊市人民医院心内一科

摘要(Abstract)：

目的探讨冠脉血运重建治疗对冠心病合并心衰患者预后的影响。方法对1163例行冠脉血运重建治疗(包括PCI和CABG)的冠心病合并心衰的患者进行回顾性分析,按左室射血分数是否正常(定义为LVEF≥50%)将患者分为左室射血分数正常组(LVEF≥50%,920例)和左室射血分数降低组(LVEF<50%,243例),分别评价患者住院期间的临床、血管造影、超声心动图等相关资料并对患者进行长期随访。平均随访时间为548天,一级终点为全因死亡率。结果左室射血分数正常组和左室射血分数降低组在住院期间死亡率差异无统计学意义(χ2=2.105,P=0.147),在随访期间累积生存率差异也无统计学意义(logrank统计值2.134,P=0.161)。Cox回归分析发现,患者年龄(HR1.093,95%CI1.040～1.148,P<0.001)为影响患者死亡的独立预测因子。结论影响行血运重建治疗的冠心病合并心衰患者的预后因素为患者年龄;在这些患者中,左室射血分数正常组和左室射血分数降低组患者临床预后相似。

关键词(KeyWords)： 心肌血管重建术;冠心病;心力衰竭;预后

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 薛增明,马长生,刘新民,康俊萍,聂绍平,董建增

参考文献(References)：

• [1]Bhatia RS,Tu JV,Lee DS,et al.Outcome of heart failure with preserved ejection fraction in a population-based study.N Engl J Med,2006,355:260-269.
• [2]Owan TE,Hodge DO,Herges RM,et al..Trends in prevalence and outcome of heart failure with preserved ejection fraction.N Engl J Med,2006,355:251-259.
• [3]Fox KF,Cowie MR,Wood DA,et al.Coronary artery disease as the cause of incident heart failure in the population.Eur Heart J,2001,22:228-236.
• [4]Dickstein K,Cohen-Solal A,Filippatos G,et al.ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure2008:the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure2008of the European Society of Cardiology.Developed in collaboration with the Heart Failure Association of the ESC(HFA)and endorsed by the European Society of Intensive Care Medicine(ESICM).Eur Heart J,2008,29:2388-2442.
• [5]Hunt SA,Baker DW,Chin MH,et al.ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult:Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines(Committee to Revise the1995Guidelines for the Evaluation and Management of Heart Failure):Developed in Collaboration With the International Society for Heart and Lung Transplantation;Endorsed by the Heart Failure Society of America.Circulation,2001,104:2996-3007.
• [6]Paulus WJ,Tschope C,Sanderson JE,et al.How to diagnose diastolic heart failure:a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the EuropeanSociety of Cardiology.Eur Heart J,2007,28:2539-2550.
• [7]Chin MH,Goldman L.Factors contributing to the hospitalization of patients with congestive heart failure.Am J Public Health,1997,87:643-648.
• [8]Kirtane AJ,Moses JW.Revascularization in heart failure:the role of percutaneous coronary intervention.Heart Fail Clin,2007,3:229-235.
• [9]Momtahen M,Abdi S,Ojaghi Z,et al.Global and regional left ventricular function improvement following successful percutaneous coronary intervention in patients with ischemic left ventricular dysfunction.Arch Iran Med,2007,10:387-389.
• [10]Allman KC,Shaw LJ,Hachamovitch R,et al.Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction:a meta-analysis.J Am Coll Cardiol,2002,39:1151-1158.
• [11]Chareonthaitawee P,Gersh BJ,Araoz PA,et al.Revascularization in severe left ventricular dysfunction:the role of viability testing.J Am Coll Cardiol,2005,46:567-574.
• [12]Kirschbaum SW,Baks T,van den Ent M,et al.Evaluation of left ventricular function three years after percutaneous recanalization of chronic total coronary occlusions.Am J Cardiol,2008,101:179-185.
• [13]Shanmugam G,Legare JF.Revascularization for ischaemic cardiomyopathy.Curr Opin Cardiol,2008,23:148-152.
• [14]Miyagishima K,Hiramitsu S,Kimura H,et al.Long term prognosis of chronic heart failure:reduced vs preserved left ventricular ejection fraction.Circ J,2009,73:92-99.
• [15]Massie BM,Carson PE,McMurray JJ,et al.Irbesartan in patients with heart failure and preserved ejection fraction.N Engl J Med,2008,359:2456-2467.
• [16]Parthasarathy HK,Pieske B,Weisskopf M,et al.A randomized,double-blind,placebo-controlled study to determine the effects of valsartan on exercise time in patients with symptomatic heart failure with preserved ejection fraction.Eur J Heart Fail,2009,11:980-989.
• [17]Carluccio E,Biagioli P,Alunni G,et al.Effect of revascularizing viable myocardium on left ventricular diastolic function in patients with ischaemic cardiomyopathy.Eur Heart J,2009,30:1501-1509.
• [18]Pusca SV,Puskas JD.Revascularization in heart failure:coronary bypass or percutaneous coronary intervention?Heart Fail Clin,2007,3:211-228.
• [19]Sedlis SP,Ramanathan KB,Morrison DA,et al.Outcome of percutaneous coronary intervention versus coronary bypass grafting for patients with low left ventricular ejection fractions,unstable angina pectoris,and risk factors for adverse outcomes with bypass(the AWESOME Randomized Trial and Registry).Am J Cardiol,2004,94:118-120.
• [20]Wallace TW,Berger JS,Wang A,et al.Impact of left ventricular dysfunction on hospital mortality among patients undergoing elective percutaneous coronary intervention.Am J Cardiol,2009,103:355-360.
• [21]Buszman P,Szkrobka I,Tendera Z,et al.Early and late results of percutaneous revascularization in patients with ischemic cardiomyopathy and decreased left ventricular ejection fraction.(Revascularisation in Heart Failure Trial,REHEAT Registry).EuroIntervention,2005,1:186-192.
• [22]Gioia G,Matthai W,Gillin K,et al.Revascularization in severe left ventricular dysfunction:outcome comparison of drug-eluting stent implantation versus coronary artery by-pass grafting.Catheter Cardiovasc Interv,2007,70:26-33.
• [23]Buszman P,Szkrobka I,Gruszka A,et al.Comparison of effectiveness of coronary artery bypass grafting versus percutaneous coronary intervention in patients with ischemic cardiomyopathy.Am J Cardiol,2007,99:36-41.